Journal of Clinical Virology
Volume 34 , Pages S1-S3 , December 2005

Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention

  • D. Lavanchy

      Affiliations

    • Corresponding Author InformationCorresponding author. World Health Organization. 20, avenue Appia, CH-1211 Geneva 27, Switzerland

References 

  1. Brooks EA, Lacey LF, Payne SL, Miller DW. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States. Am J Manag Care. 2001;7(7):677–682
  2. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336(26):1855–1859
  3. el-Saved HE, Abaza SM, Mehanna S, Winch PJ. The prevalence of hepatitis B and C infections among immigrants to a newly reclaimed area endemic for Schistosoma mansoni in Sinai, Egypt. Acta Trop. 1997;68(2):229–237
  4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745–750
  5. Giacchino R, Zancan L, Vajro P, Verucchi G, Resti M, Barbera C, et al. Hepatitis B virus infection in native versus immigrant or adopted children in Italy following the compulsory vaccination. Infection. 2001;29(4):188–191
  6. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ. 1999;77(10):801–817
  7. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337(24):1733–1745
  8. Lemon SM, Layden TJ, Seeff L, Suzuki H, Nishioka K, Mishiro S, et al. The 20th United States-Japan Joint Hepatitis Panel Meeting. Hepatology. 2000;31(3):800–806
  9. (Suppl) Margolis HS, Schatz GC, Kane MA. Development of recommendations for control of hepatitis B virus infections: the role of cost analysis. discussion S93-S94 Vaccine. 1990;8:S69–S73
  10. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135(9):796–800
  11. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153–156
  12. Pokorski RJ, Ohlmer U. Long-term morbidity and mortality in Chinese insurance applicants infected with the hepatitis B virus. J Insur Med. 2001;33(2):143–164
  13. Rosenberg D, Cook S, Eaton S, Saunders W, Lanza L. The epidemiology, treatment patterns and resource utilization of hepatitis B patients in a large insured New England population. Pharmcoepidmiol Drug Saf. 1998;7(suppl 2):S132
  14. Stroffolini T, Mele A, Tosti ME, Gallo G, Balocchini E, Ragni P, et al. The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy. J Hepatol. 2000;33(6):980–985
  15. VHPB . Prevention and control of viral hepatitis in migrants and refugees. VHPB-meeting. Viral Hepatitis. 2000;8(2):1–7
  16. WHO . Hepatitis B Vaccine-making global progress. In: Update, Expanded Programme on Immunization. WHO; 1996;
  17. WHO . The World Health Report. WHO; 1997;
  18. (Revised October 2000) WHO . Hepatitis B Fact Sheet No. 204. Web site WHO; 2000;
  19. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferonalpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med. 1995;122(9):664–675
  20. Yang BM, Paik SW, Hahn OS, Yi DH, Choi MS, Payne S. Economic evaluation of the societal costs of hepatitis B in South Korea. J Gastroenterol Hepatol. 2001;16(3):301–318
  21. Yu MC, Yuan JM, Govindarajan S, Ross RK. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol. 2000;14(8):703–709

PII: S1386-6532(05)00384-7

Journal of Clinical Virology
Volume 34 , Pages S1-S3 , December 2005

Article Tools